TherapeuticsMD (TXMD) Share-based Compensation (2010 - 2026)

TherapeuticsMD (TXMD) has reported Share-based Compensation for 17 consecutive years, with $130.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 256047.36% year-over-year to $130.7 million; the trailing twelve-month figure through Jun 2026 stood at $130.7 million (up 256047.36% YoY), and the FY2025 full-year result was -$2.0 million, down 4.66% from the prior year.
• Share-based Compensation improved to $130.7 million in Q2 2026 per TXMD's latest filing, from $105212.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $130.7 million in Q2 2026 and bottomed at -$629000.0 in Q1 2024.
• Historically, Share-based Compensation has averaged $8.6 million across 5 years, with a median of $169106.0 in 2023.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation slumped 1005.36% in 2025, then soared 256047.36% in 2026.
• Over 5 years, Share-based Compensation stood at $1.1 million in 2022, then soared by 123.27% to $2.5 million in 2023, then tumbled by 102.28% to -$56000.0 in 2024, then plunged by 1005.36% to -$619000.0 in 2025, then soared by 21216.64% to $130.7 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $130.7 million, $105212.0, and -$619000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.